Strains Matter: What a New Global Study Reveals About Infant Gut Health

When it comes to your baby’s gut, the details matter. Not just the type of bacteria or the species, but the strain.

A recent publication from the Lawley group in the UK — “Genomic atlas of Bifidobacterium infantis and B. longum informs infant probiotic design”  — helps explain why.

The researchers analyzed more than 4,000 strains of Bifidobacterium infantis collected from infants around the world. What they discovered confirms something important for modern parents: Not all B. infantis are the same — and many probiotics don’t reflect what today’s babies actually need. Let’s unpack what that means.

Why Bifidobacterium infantis Is So Important in Early Life

In the first months of life, your baby’s gut microbiome helps shape:

• Immune system development

• Inflammation balance

• Gut barrier function

• Risk of atopic disease

One of the key players in this early ecosystem is Bifidobacterium infantis.

This bacterium has a special relationship with breast milk. Human milk contains complex sugars called human milk oligosaccharides (HMOs). Babies can’t digest them — they’re designed to feed specific beneficial microbes.

Certain strains of B. infantis are uniquely equipped to consume HMOs efficiently. When they do, they help create a gut environment that supports immune education and reduces inflammatory stress.

But here’s where the new research changes the conversation.

4,000+ Strains — And They’re Not All Equal

The Lawley group’s genomic atlas examined over 4,000 B. infantis strains globally and found significant functional differences between strains.

Some strains are highly efficient at consuming HMOs. Others differ in how they metabolize carbohydrates. Some are better adapted to colonize the infant gut than others.

In other words: The label “B. infantis” doesn’t guarantee identical function.

Just like dog breeds are all dogs (but behave very differently), bacterial strains within the same species can vary in meaningful biological ways. For infant gut health, that variation matters.

The Problem With Historical Probiotics

One of the most important findings in the paper is this: The diversity of B. infantis strains found worldwide is poorly captured by historical probiotic strains.

Many commercially available B. infantis probiotics trace back to a small number of older lineages. These strains were isolated decades ago — and according to the authors, they may not reflect the strains naturally circulating in infants today.

Even more importantly, the researchers note that some of these older probiotic strains may not be well suited for natural colonization of the infant gut.

Colonization matters. A probiotic that passes through temporarily is different from one that establishes and supports the ecosystem during a critical developmental window.

This is a shift in thinking: It’s not just about adding bacteria. It’s about restoring the right strains — ones adapted for today’s infants and environments.

What This Means for Modern Babies

In our own My Baby Biome study, we found that:

• 90% of babies are missing one or more key strains of Bifidobacterium.

• About 25% had no detectable Bifidobacterium at all.

• 3 in 4 babies with low levels of healthy gut bacteria were at higher risk of allergies, eczema, and asthma.

Modern life — including C-sections, antibiotic exposure, and reduced intergenerational microbial transfer — likely plays a role. Taken together, these findings suggest that many modern babies are starting life without microbes that historically helped guide early immune development — raising an important question: how can we restore them? Probiotics are one solution, and the choice of strain matters. 

A New Generation of Infant Probiotics

Given that strains vary in their ability to metabolize HMOs, colonize the gut, and support immune development, probiotic design should account for this functional diversity. Persephone’s Synergistic Synbiotic was built around this updated understanding of infant microbiome science:

• Strain-level selection matters

• Colonization potential matters

• Functional capacity matters

• Supporting the ecosystem — not just adding bacteria — matters

Rather than relying on historical strains that may not reflect modern infant needs, new formulations can be built from carefully selected, novel strains designed for effective colonization and microbiome support.

This is where microbiome science is heading: precision, not guesswork.

The Takeaway: The Future of Infant Gut Health Is Strain-Specific

The Lawley group’s genomic atlas makes one thing very clear: Strains matter.

There are thousands of versions of B. infantis, and they don’t all function the same way. Historical probiotics capture only a fraction of that diversity — and may not be suited to colonize modern infants effectively. For parents, this doesn’t mean alarm. It means clarity. Modern science now allows us to design solutions that reflect this subtlety.

At Persephone, we believe supporting infant gut health should feel calm, informed, and rooted in evidence — not hype. Because when we understand the science at the strain level, we can support babies at the foundational level.

*Medical Disclaimer

The information provided on this blog is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Every baby is unique, and health decisions should always be made in partnership with a qualified healthcare professional. If you have questions or concerns about your child’s health, diet, or development, please consult your pediatrician or another trusted healthcare provider before making changes.

References:

1. Shao, Y., Wang, S., Gichuki, B. M., et al. (2026). Genomic atlas of Bifidobacterium infantis and B. longum informs infant probiotic discovery for global health. Cell. https://doi.org/10.1016/j.cell.2026.01.007.

2. Jarman, J.B., Torres, P.J., Stromberg, S. et al. Bifidobacterium deficit in United States infants drives prevalent gut dysbiosis. Commun Biol 8, 867 (2025). https://doi.org/10.1038/s42003-025-08274-7.